Literature DB >> 33155773

Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression.

Wei Liu1, Congwen Zhuang1, Tengfei Huang1, Shengsheng Yang1, Meiqing Zhang1, Baoquan Lin2, Yi Jiang3.   

Abstract

OBJECTIVE: This study aimed to identify critical genes involved in the tumor biology of lung cancer via datamining of The Cancer Genome Atlas (TCGA) with special focus on gene copy number variation.
METHODS: Genomic deletion and amplification were analyzed with cBioportal online tools. Relative expression of Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) was analyzed by both real-time polymerase chain reaction (PCR) and Western blot. The abundance of methylthioadenosine phosphorylase (MTAP) and epithelial-mesenchymal transition markers were analyzed by real-time PCR. Cell proliferation was determined by cell counting kit-8 method and cell viability was measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The cell migration and invasion were measured with transwell chamber assay, and migrative capacity was further evaluated by wound healing assay.
RESULTS: We found the frequent loss of CDKN2A was associated with its downregulation in lung cancer, and siRNA-mediated CDNKN2A knockdown significantly stimulated cell proliferation, invasion, and migration. Mechanistically, we unraveled that MTAP, which was positively correlated with CDKN2A, predominantly mediated the antitumoral function of CDKN2A in lung cancer.
CONCLUSION: Our study consolidated the involvement of CDKN2A-MTAP signaling in the context of lung cancer.
© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Entities:  

Keywords:  CDKN2A; MTAP; copy number variation; lung cancer

Mesh:

Substances:

Year:  2020        PMID: 33155773      PMCID: PMC7767555          DOI: 10.1002/mgg3.1521

Source DB:  PubMed          Journal:  Mol Genet Genomic Med        ISSN: 2324-9269            Impact factor:   2.183


  30 in total

1.  Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.

Authors:  Konstantinos J Mavrakis; E Robert McDonald; Michael R Schlabach; Eric Billy; Gregory R Hoffman; Antoine deWeck; David A Ruddy; Kavitha Venkatesan; Jianjun Yu; Gregg McAllister; Mark Stump; Rosalie deBeaumont; Samuel Ho; Yingzi Yue; Yue Liu; Yan Yan-Neale; Guizhi Yang; Fallon Lin; Hong Yin; Hui Gao; D Randal Kipp; Songping Zhao; Joshua T McNamara; Elizabeth R Sprague; Bing Zheng; Ying Lin; Young Shin Cho; Justin Gu; Kenneth Crawford; David Ciccone; Alberto C Vitari; Albert Lai; Vladimir Capka; Kristen Hurov; Jeffery A Porter; John Tallarico; Craig Mickanin; Emma Lees; Raymond Pagliarini; Nicholas Keen; Tobias Schmelzle; Francesco Hofmann; Frank Stegmeier; William R Sellers
Journal:  Science       Date:  2016-02-11       Impact factor: 47.728

Review 2.  A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Authors:  Hai-Yan Tu; E-E Ke; Jin-Ji Yang; Yue-Li Sun; Hong-Hong Yan; Ming-Ying Zheng; Xiao-Yan Bai; Zhen Wang; Jian Su; Zhi-Hong Chen; Xu-Chao Zhang; Zhong-Yi Dong; Si-Pei Wu; Ben-Yuan Jiang; Hua-Jun Chen; Bin-Chao Wang; Chong-Rui Xu; Qing Zhou; Ping Mei; Dong-Lan Luo; Wen-Zhao Zhong; Xue-Ning Yang; Yi-Long Wu
Journal:  Lung Cancer       Date:  2017-11-07       Impact factor: 5.705

Review 3.  The biology and treatment of EML4-ALK non-small cell lung cancer.

Authors:  Takaaki Sasaki; Scott J Rodig; Lucian R Chirieac; Pasi A Jänne
Journal:  Eur J Cancer       Date:  2010-04-24       Impact factor: 9.162

4.  MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients.

Authors:  C-Y Su; Y-C Chang; Y-C Chan; T-C Lin; M-S Huang; C-J Yang; M Hsiao
Journal:  Eur J Surg Oncol       Date:  2014-06-12       Impact factor: 4.424

5.  Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).

Authors:  M Schmid; D Malicki; T Nobori; M D Rosenbach; K Campbell; D A Carson; C J Carrera
Journal:  Oncogene       Date:  1998-11-19       Impact factor: 9.867

6.  Detection of FHIT and p16 mRNA deletion in biopsy specimens obtained by bronchoscopy for the diagnosis of lung cancer.

Authors:  Ping Chen; Jian Li; Yi Wang; Li-Rong Zhu; Yi-Ming Hu; Xing-Ping Tong
Journal:  Int J Biol Markers       Date:  2013-09-27       Impact factor: 2.659

7.  Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.

Authors:  G I Shapiro; C D Edwards; L Kobzik; J Godleski; W Richards; D J Sugarbaker; B J Rollins
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

8.  Methylation of P16 in exhaled breath condensate for diagnosis of non-small cell lung cancer.

Authors:  Ping Xiao; Jian-rong Chen; Feng Zhou; Chen-xi Lu; Qichan Yang; Guo-hua Tao; Yi-jiang Tao; Jing-liang Chen
Journal:  Lung Cancer       Date:  2013-09-25       Impact factor: 5.705

9.  Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer.

Authors:  Anna D Panani; Katerina Maliaga; Athanasia Babanaraki; Ion Bellenis
Journal:  Anticancer Res       Date:  2009-11       Impact factor: 2.480

10.  P16INK4a gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis.

Authors:  Lei Tuo; Sha Sha; Zhang Huayu; Ke Du
Journal:  Thorac Cancer       Date:  2018-06-21       Impact factor: 3.500

View more
  4 in total

1.  Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report.

Authors:  Junru Ye; Yutong Ma; Qiuxiang Ou; Junrong Yan; Bin Ye; Yuping Li
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

2.  A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma.

Authors:  Liping Zhu; Zhiqiang Wang; Yilan Sun; Georgios Giamas; Justin Stebbing; Zhentao Yu; Ling Peng
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

3.  Co-occurrence of CDKN2A/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma.

Authors:  Yuan Peng; Yonghong Chen; Mengmeng Song; Xiaoyue Zhang; Pansong Li; Xian Yu; Yusheng Huang; Ni Zhang; Liyan Ji; Lei Xia; Xuefeng Xia; Xin Yi; Benxu Tan; Zhenzhou Yang
Journal:  Mol Oncol       Date:  2022-03-15       Impact factor: 7.449

4.  Transcriptomic data exploration of consensus genes and molecular mechanisms between chronic obstructive pulmonary disease and lung adenocarcinoma.

Authors:  Siyu Zhang; Kun Pang; Xinyu Feng; Yulan Zeng
Journal:  Sci Rep       Date:  2022-08-02       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.